Glenmark reports revenue growth of 26% for Q1 FY 2021-22

Glenmark Pharmaceuticals Limited, a research‐led global integrated pharmaceutical company, today announced its financial results for the first quarter ended June 30, 2021.

For the First Quarter of FY 2021-22, Glenmark’s consolidated revenue was at Rs. 29,649 Mn. as against Rs. 23,448 Mn recording an increase of 26%.

Highlights for Q1 FY 2021‐22

• India Business grew by 57 % YoY to Rs. 12,250 Mn.
• North America Business recorded growth of 6% YoY to Rs. 7,878 Mn.
• Europe Business grew by 12% YoY to Rs. 3,059 Mn.
• ROW Business grew by 27% YoY to Rs. 2,686 Mn.
• API Business grew by 29% YoY to Rs. 3040 Mn.
• EBITDA of Rs. 5,736 Mn grew by 20% YoY with margins of 19%.

MB Bureau